CompanyI-MAB Biopharma Co., Ltd.
China
I-Mab is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company's mission is to bring transformational medicines to patients through innovation.
Private/Public:
public
Phone:86-21-6057 8000
Email:[email protected]
Website:https://www.i-mabbiopharma.com/
Address:Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, 201210, China
2017
Since
1
Country
2
Top Service Categories
7
Sub-Service Categories
Bioanalytical
Bioanalytical Assay Services
Discovery and Preclinical
Chemistry/Discovery Tech./In silico services
Efficacy In Vitro
China
- (09.Jun.2022) Ferring Announces New Collaboration for Development of Olamkicept
- (31.May.2022) I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency
- (26.May.2022) I-Mab Reports Latest Phase 2 Clinical Data of Its Differentiated CD73 Antibody Uliledlimab
- (05.May.2022) I-Mab Provides Updates on Status Under Holding Foreign Companies Accountable Act
- (28.Apr.2022) I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- (31.Mar.2022) I-Mab Announces Voluntary Lock-Ups by Key Shareholders and Senior Management for Long-Term Commitment
- (29.Mar.2022) I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
- (15.Mar.2022) I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
- (03.Mar.2022) I-Mab Receives FDA Orphan Drug Designation for Its Novel Claudin 18.2 X 4-1bb Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
- (28.Jan.2022) I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
- (18.Jan.2022) I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab With Toripalimab in Patients With Advanced Solid Tumors
- (14.Jan.2022) I-Mab Announces Execution of Senior Management Team Share Purchase Plan
- (12.Jan.2022) I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination With Pembrolizumab in Advanced Solid Tumors
- (06.Jan.2022) I-Mab Announces Senior Management Team Share Purchase Plan
- (27.Dec.2021) I-Mab Announces IND Approval From China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination With Pembrolizumab in Solid Tumors
- (20.Dec.2021) I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
- (15.Dec.2021) I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
- (14.Dec.2021) I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination With Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021
- (13.Dec.2021) I-Mab Biopharma and AGC Biologics Partner on Late-Phase Project
- (08.Dec.2021) I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
- (07.Dec.2021) I-Mab to Pursue Dual Listing Plan on the Main Board of the Stock Exchange of Hong Kong Limited
- (03.Dec.2021) I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab With Atezolizumab in Patients With Selected Advanced Solid Tumors
- (10.Nov.2021) I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa
- (09.Nov.2021) I-Mab and ABL Bio Report Preclinical Data of 4-1bb-Targeting Bispecific Antibodies at 2021 SITC
- (08.Nov.2021) I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE
- (01.Nov.2021) I-Mab Strengthens Senior Executive Team With New Chief Financial Officer and Chief Strategy Officer Appointments
- (26.Oct.2021) I-Mab Announces Strategic Partnership With Sinopharm in Preparation for Launch of Its Innovative Assets in China
- (22.Oct.2021) I-Mab Expands U.S. Footprint With New R&D Site in San Diego
- (21.Oct.2021) First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients With Immunoglobulin a Nephropathy
- (18.Oct.2021) I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination With PD-1 Therapy in China
- (13.Oct.2021) I-Mab Advances Late-Stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
- (05.Oct.2021) I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
- (30.Sep.2021) I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
- (28.Sep.2021) I-Mab Announces Acceptance of IND Application From China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination With Pembrolizumab in Solid Tumors
- (13.Sep.2021) I-Mab Added to FTSE ESG Index Series
- (02.Sep.2021) I-Mab Added to FTSE Russell Global Equity Index Series
- (31.Aug.2021) I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
- (19.Aug.2021) I-Mab Announces Establishment of Environmental, Social and Governance Committee
- (11.Aug.2021) I-Mab Reports Positive Interim Analysis From Phase 2/3 Study of Its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients With Severe COVID-19
- (04.Aug.2021) ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an Anti-Lag-3/Pd-L1 Bispecific Antibody
- (30.Jul.2021) I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
- (29.Jul.2021) I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company Up to US$40 Million
- (28.Jul.2021) I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination With PD-1 Therapy in China
- (27.Jul.2021) I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
- (09.Jul.2021) I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
- (09.Jul.2021) I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
- (09.Jul.2021) ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-Pd-L1 X 4-1bb Bispecific Antibody
- (01.Jul.2021) I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio
- (30.Jun.2021) I-Mab Honored With Top Rankings by Institutional Investor